Products for Research Use Only

Ruzotolimod

CAT: 0804-HY-145592-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-145592-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ruzotolimod (RO7020531) is an orally active TLR7 agonist. Ruzotolimod inhibits WHV viral replication and, in combination with RO-7049389 , inhibits AAV-HBV viral load. Ruzotolimod can be used to study infection with COVID-19 or SARS-CoV-2[1][2][3][4].
CAS Number
1948241-60-8
Product Name Alternative
RO7020531; RG7854
UNSPSC
12352005
Target
HBV; SARS-CoV; Toll-like Receptor (TLR)
Type
Reference compound
Related Pathways
Anti-infection; Immunology/Inflammation
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/ruzotolimod.html
Purity
99.92
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C1N([C@]([C@@H](C2)O)([H])O[C@]2([H])[C@H](CC)OC(C)=O)C3=NC(N)=NC=C3S1
Molecular Formula
C14H18N4O5S
Molecular Weight
354.38
References & Citations
[1]Qingyan BO, et al. Method of treating virus infection using a tlr7 agonist. Patent WO2021130195A1.|[2]Jiang Q, et al. Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod[J]. Clinical and Translational Science, 2024, 17 (8) : e13896.|[3]Croasdell G. European Association for the Study of the Liver-53rd International Liver Congress. Paris, France-April 11-15, 2018. Drugs of the Future, 2018, 43 (7) .|[4]Wildum S, et al. Toll-Like Receptor 7 Agonist RG7854 Mediates Therapeutic Efficacy and Seroconversion in Woodchucks With Chronic Hepatitis B. Front Immunol. 2022 May 23;13:884113.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1

Alternative Products

Popular Products